Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose - PubMed
- ️Sat Jan 01 2005
. 2005 Jun 2;352(22):2285-93.
doi: 10.1056/NEJMoa044503.
Affiliations
- PMID: 15930419
- DOI: 10.1056/NEJMoa044503
Free article
Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose
Mark J Rieder et al. N Engl J Med. 2005.
Free article
Abstract
Background: The management of warfarin therapy is complicated by a wide variation among patients in drug response. Variants in the gene encoding vitamin K epoxide reductase complex 1 (VKORC1) may affect the response to warfarin.
Methods: We conducted a retrospective study of European-American patients receiving long-term warfarin maintenance therapy. Multiple linear-regression analysis was used to determine the effect of VKORC1 haplotypes on the warfarin dose. We determined VKORC1 haplotype frequencies in African-American, European-American, and Asian-American populations and VKORC1 messenger RNA (mRNA) expression in human liver samples.
Results: We identified 10 common noncoding VKORC1 single-nucleotide polymorphisms and inferred five major haplotypes. We identified a low-dose haplotype group (A) and a high-dose haplotype group (B). The mean (+/-SE) maintenance dose of warfarin differed significantly among the three haplotype group combinations, at 2.7+/-0.2 mg per day for A/A, 4.9+/-0.2 mg per day for A/B, and 6.2+/-0.3 mg per day for B/B (P<0.001). VKORC1 haplotype groups A and B explained approximately 25 percent of the variance in dose. Asian Americans had a higher proportion of group A haplotypes and African Americans a higher proportion of group B haplotypes. VKORC1 mRNA levels varied according to the haplotype combination.
Conclusions: VKORC1 haplotypes can be used to stratify patients into low-, intermediate-, and high-dose warfarin groups and may explain differences in dose requirements among patients of different ancestries. The molecular mechanism of this warfarin dose response appears to be regulated at the transcriptional level.
Copyright 2005 Massachusetts Medical Society.
Similar articles
-
Limdi NA, Beasley TM, Crowley MR, Goldstein JA, Rieder MJ, Flockhart DA, Arnett DK, Acton RT, Liu N. Limdi NA, et al. Pharmacogenomics. 2008 Oct;9(10):1445-58. doi: 10.2217/14622416.9.10.1445. Pharmacogenomics. 2008. PMID: 18855533 Free PMC article.
-
Lee SC, Ng SS, Oldenburg J, Chong PY, Rost S, Guo JY, Yap HL, Rankin SC, Khor HB, Yeo TC, Ng KS, Soong R, Goh BC. Lee SC, et al. Clin Pharmacol Ther. 2006 Mar;79(3):197-205. doi: 10.1016/j.clpt.2005.11.006. Clin Pharmacol Ther. 2006. PMID: 16513444
-
Limdi NA, Wadelius M, Cavallari L, Eriksson N, Crawford DC, Lee MT, Chen CH, Motsinger-Reif A, Sagreiya H, Liu N, Wu AH, Gage BF, Jorgensen A, Pirmohamed M, Shin JG, Suarez-Kurtz G, Kimmel SE, Johnson JA, Klein TE, Wagner MJ; International Warfarin Pharmacogenetics Consortium. Limdi NA, et al. Blood. 2010 May 6;115(18):3827-34. doi: 10.1182/blood-2009-12-255992. Epub 2010 Mar 4. Blood. 2010. PMID: 20203262 Free PMC article.
-
Warfarin dose and the pharmacogenomics of CYP2C9 and VKORC1 - rationale and perspectives.
Yin T, Miyata T. Yin T, et al. Thromb Res. 2007;120(1):1-10. doi: 10.1016/j.thromres.2006.10.021. Epub 2006 Dec 11. Thromb Res. 2007. PMID: 17161452 Review.
-
Oldenburg J, Bevans CG, Fregin A, Geisen C, Müller-Reible C, Watzka M. Oldenburg J, et al. Thromb Haemost. 2007 Sep;98(3):570-8. Thromb Haemost. 2007. PMID: 17849045 Review.
Cited by
-
Hemati H, Nosrati M, Hasanzad M, Rahmani P, Fariman S, Sarabi M, Shirvani S, Sadeghipour P, Nikfar S. Hemati H, et al. Iran J Pharm Res. 2024 May 14;23(1):e143898. doi: 10.5812/ijpr-143898. eCollection 2024 Jan-Dec. Iran J Pharm Res. 2024. PMID: 39108643 Free PMC article.
-
Pharmacokinetic and pharmacodynamic variability of fluindione in octogenarians.
Comets E, Diquet B, Legrain S, Huisse MG, Godon A, Bruhat C, Chauveheid MP, Delpierre S, Duval X, Berrut G, Verstuyft C, Aumont MC, Mentré F. Comets E, et al. Clin Pharmacol Ther. 2012 May;91(5):777-86. doi: 10.1038/clpt.2011.309. Clin Pharmacol Ther. 2012. PMID: 22472992 Free PMC article.
-
Jang SW, Rho TH, Kim DB, Cho EJ, Kwon BJ, Park HJ, Shin WS, Kim JH, Lee JM, Moon KW, Oh YS, Yoo KD, Youn HJ, Lee MY, Chung WS, Seung KB, Kim JH. Jang SW, et al. Korean Circ J. 2011 Oct;41(10):578-82. doi: 10.4070/kcj.2011.41.10.578. Epub 2011 Oct 31. Korean Circ J. 2011. PMID: 22125556 Free PMC article.
-
Valentin II, Vazquez J, Rivera-Miranda G, Seip RL, Velez M, Kocherla M, Bogaard K, Cruz-Gonzalez I, Cadilla CL, Renta JY, Feliu JF, Ramos AS, Alejandro-Cowan Y, Gorowski K, Ruaño G, Duconge J. Valentin II, et al. Ann Pharmacother. 2012 Feb;46(2):208-18. doi: 10.1345/aph.1Q190. Epub 2012 Jan 24. Ann Pharmacother. 2012. PMID: 22274142 Free PMC article.
-
Vitamin K nutrition, metabolism, and requirements: current concepts and future research.
Shearer MJ, Fu X, Booth SL. Shearer MJ, et al. Adv Nutr. 2012 Mar 1;3(2):182-95. doi: 10.3945/an.111.001800. Adv Nutr. 2012. PMID: 22516726 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Research Materials